Skip to main content

OGEN

Stock
Health Care
Biotechnology

Performance overview

OGEN Price
Price Chart

Forward-looking statistics

Beta
0.54
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Company info

SectorHealth Care
IndustryBiotechnology
Employees11
Market cap$7.5M

Fundamentals

Enterprise value$1.9M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity1855.20

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$30.60
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$3M
Put-call ratio

Macro factor sensitivity

Growth-10.4
Credit+14.8
Liquidity+5.7
Inflation-13.2
Commodities-5.3
Interest Rates-3.9

Valuation

Dividend yield0.00%
PEG Ratio-0.14
Price to sales
P/E Ratio-0.14
Enterprise Value to Revenue
Price to book7.97

Upcoming events

Next earnings dayMay 12, 2023
Next dividend day
Ex. dividend day

News

Oragenics Extends Collaboration with NRC Canada For Omicron-Specific Vaccine

Oragenics Inc (NYSE: OGEN) has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) to enable Oragenics to pursue an intranasal vaccine designed against omicron variant.  The NRC cell expression technologies provide Oragenics with a platform to generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern.

Benzinga (December 20, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free